Picton Mahoney Asset Management Sells 96,721 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Picton Mahoney Asset Management cut its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 13.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 617,892 shares of the company’s stock after selling 96,721 shares during the period. Picton Mahoney Asset Management’s holdings in Teva Pharmaceutical Industries were worth $12,483,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of TEVA. Menora Mivtachim Holdings LTD. raised its stake in shares of Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after purchasing an additional 9,303,978 shares in the last quarter. Soundwatch Capital LLC acquired a new position in Teva Pharmaceutical Industries during the second quarter worth $143,533,000. Maverick Capital Ltd. increased its holdings in Teva Pharmaceutical Industries by 14,351.6% during the second quarter. Maverick Capital Ltd. now owns 4,377,690 shares of the company’s stock worth $73,370,000 after buying an additional 4,347,398 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 13.6% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock valued at $658,161,000 after acquiring an additional 3,896,790 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide $400 million to fund development of duvakitug (TL1A antibody), lowering capital risk for Teva’s late‑stage IBD program and accelerating a potential new specialty biologic growth engine. Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug
• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and nudged its price target higher to $41, signaling continued analyst confidence and providing a visible upside reference for investors. Benzinga coverage of Piper Sandler
• Neutral Sentiment: Coverage highlighting generic-drug headwinds also notes Teva’s strategic push into complex generics and biosimilars as a hedge against price pressure—this supports longer-term growth but doesn’t remove near-term margin risk. 3 Generic Drug Stocks to Watch Despite Industry Headwinds
• Neutral Sentiment: Broader industry commentary about AI adoption in pharma could benefit Teva over time through R&D efficiency and manufacturing optimization, but it’s a longer‑horizon factor rather than an immediate catalyst. Pharmaceutical Executive Daily: Pharma Industry’s AI Adoption
• Negative Sentiment: An executive (EVP Eliyahu Sharon Kalif) disclosed a large sale of 345,810 shares (~$11.6M at the trade price), which can be interpreted by some investors as insider profit‑taking and can weigh on sentiment. Teva EVP Sells 345,810 Shares
• Negative Sentiment: High‑profile investor Stanley Druckenmiller trimmed his TEVA position per 13F filings, a notable name‑level reduction that can be read as profit‑taking and may reduce momentum among discretionary institutional buyers. Billionaire Stanley Druckenmiller Dumped Teva
• Negative Sentiment: A dividend-focused piece recommends an alternative high-yield competitor over Teva, which could damp demand from income investors who are comparing yields and stability. Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at $170,630. This represents a 68.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Roberto Mignone sold 77,400 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the sale, the director directly owned 367,600 shares of the company’s stock, valued at $11,116,224. This represents a 17.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 767,870 shares of company stock worth $23,888,014. 0.49% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on TEVA. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Jefferies Financial Group lifted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Truist Financial upped their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Stock Up 1.8%

Teva Pharmaceutical Industries stock opened at $32.87 on Thursday. The company’s 50-day moving average price is $33.03 and its two-hundred day moving average price is $26.07. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market cap of $37.79 billion, a P/E ratio of 27.39, a P/E/G ratio of 10.80 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.